

Medical Coverage Policy | Vestibular Function Tests



EFFECTIVE DATE: 01 | 01 | 2017

POLICY LAST REVIEWED: 03 | 06 | 2024

OVERVIEW

Dizziness, vertigo, and balance impairments can arise from a loss of vestibular function. A number of established laboratory-based tests are used to evaluate whether the symptoms are due to dysfunction of the semicircular canals. These tests are based on the vestibulo-ocular reflex, which is an involuntary movement of the eyes (nystagmus) in response to vestibular stimulation. Established laboratory tests include electronystagmography (ENG) and videonystagmography (VNG) test batteries, caloric stimulation, and rotational chair testing. Vestibular evoked myogenic potentials (VEMPs), triggered by sound and vibration, are also being evaluated for the diagnosis of otolith dysfunction.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage Plans

Vestibular function testing using an electronystagmography and videonystagmography testing batteries, caloric testing, or rotational chair testing may be considered medically necessary in individuals with symptoms of a vestibular disorder (eg, dizziness, vertigo, imbalance) and a clinical evaluation, including maneuvers such as the Dix-Hallpike test if indicated, has failed to identify the cause of the symptoms.

Vestibular function testing for the assessment of typical benign paroxysmal positional vertigo that can be diagnosed clinically, repeat vestibular function testing when treatment resolves symptoms laboratory based vestibular function tests not described above are not covered as the evidence is insufficient to determine that the technology is likely to improve the net health outcome.

Vestibular evoked myogenic potential tests are considered not covered as the evidence is insufficient to determine that the technology is likely to improve the net health outcome.

Commercial Products

Vestibular function testing using an electronystagmography and videonystagmography testing batteries, caloric testing, or rotational chair testing may be considered medically necessary in individuals with symptoms of a vestibular disorder (e.g., dizziness, vertigo, imbalance) and a clinical evaluation, including maneuvers such as the Dix-Hallpike test if indicated, has failed to identify the cause of the symptoms.

Vestibular function testing for the assessment of typical benign paroxysmal positional vertigo that can be diagnosed clinically, repeat vestibular function testing when treatment resolves symptoms laboratory based vestibular function tests not described above are not medically necessary as the evidence is insufficient to determine that the technology is likely to improve the net health outcome.

Vestibular evoked myogenic potential tests are considered not medically necessary as evidence is insufficient to determine that the technology is likely to improve the net health outcome.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable diagnostic and not medically necessary benefits/coverage.

BACKGROUND

The vestibular system is an important component in balance control. It includes 5 end organs, 3 semicircular canals sensitive to head rotations, and 2 otolith organs (sacculae, utricle) that sense gravity and straight-line (forward, backward, left, right, downward or upward) accelerations. Vertigo is the primary symptom of vestibular dysfunction. It can be experienced as illusory movement such as spinning, swaying, or tilting. Vertigo may be associated with a feeling of being pushed or pulled to the ground, blurred vision, nausea and vomiting, or postural and gait instability. Vertigo may arise from damage or dysfunction of the vestibular labyrinth, vestibular nerve, or central vestibular structures in the brainstem.

Vertigo may be caused by loose particles (otoconia) from the otolith organs that pass into one of the semicircular canals, most frequently the posterior canal. Specific head movements cause the particle to stimulate the canal, causing brief benign paroxysmal positional vertigo (BPPV). BPPV can usually be diagnosed clinically based on history of positional vertigo, response to the Dix-Hallpike maneuver or lateral roll tests, and resolution of symptoms with canal repositioning maneuvers.

Testing

If vertigo cannot be attributed to BPPV based on history, symptoms, or response to the standard maneuvers, a number of laboratory-based tests can be used to determine whether the vertigo is due to loss of vestibular function.^{1,2} These tests are based on the vestibulo-ocular reflex, which is an involuntary beating movement of the eyes (nystagmus) in response to vestibular stimulation. Nystagmus induced by these tests can help to distinguish between central and peripheral etiologies, in addition to determining whether the deficit is unilateral or bilateral. The typical tests include the electronystagmography (ENG) or videonystagmography (VNG) test batteries, caloric testing, and rotational chair testing.

ENG/VNG Test Batteries

The ENG/VNG test batteries include oculomotor evaluation and positional testing. ENG uses electrodes at the canthus of the eyes to detect nystagmus while VNG uses infrared video monitoring with goggles to measure nystagmus.

Caloric Testing

Caloric testing evaluates unilateral vestibular function. In the caloric test, warm or cold water or warm or cold air, is introduced into each of the external ear canals. In some descriptions, caloric testing is conducted as part of ENG/VNG test batteries.

Rotational Chair Testing

The rotational chair test evaluates bilateral vestibular function. Rotational chair devices include a lightproof booth, computer-driven chair with a head restraint that rotates around a vertical axis, ENG recording, an infrared camera, and a 2-way communication system. Typically, the chair is rotated in 4 different patterns, constant acceleration followed by deceleration, rotating followed by a rapid stop, rotating at progressively increasing velocities, and alternating directions.

Passive rotational testing without a rotational chair may be performed when the rotational chair is not available. For the head impulse test, the patient is instructed to keep his or her eyes on a target. The examiner then turns the head rapidly by about 15°. With passive whole body testing the examiner rotates the whole body to the rhythm of a metronome.

Vestibular Evoked Myogenic Potential Testing

Vestibular evoked myogenic potential (VEMP) tests are newer techniques that use loud sound (eg, click, tone burst) or bone vibration (e.g., tendon hammer tap to the forehead or mastoid) to assess otolith function.³ Both the saccule and utricle are sensitive to sound as well as vibration and movement.

Cervical VEMPs (cVEMPs) are measured by surface electrodes on the ipsilateral sternocleidomastoid (SCM) muscle in the neck and are thought to originate primarily in the saccule. The cVEMP response was first described more than 20 years ago. Abnormality in any part of the auditory cVEMP pathway (saccule, inferior vestibular nerve, vestibular nucleus, medial vestibulospinal tract, the accessory nucleus, the eleventh nerve, SCM) can affect the response.

Ocular VEMPs (oVEMPs) detect subtle activity of an extraocular muscle using surface electrodes under the contralateral eye during an upward gaze and are thought to be due primarily to stimulation of the utricle. The vestibulo-ocular reflex stimulated by sound or vibration is very small, but synchronous bursts of activity of the extraocular muscles can be detected by electromyography. Lesions that affect the oVEMP may occur in the utricle, superior vestibular nerve, vestibular nucleus, and the crossed vestibulo-ocular reflex pathways.

Treatment

The central vestibular system is able to compensate for loss of peripheral vestibular function. Thus, the primary therapy for peripheral vestibular dysfunction is exercise-based and includes exercises to promote gaze stability, habituate symptoms, and improve balance and gait.⁴ Medications such as vestibular suppressants or antiemetics may be used in the acute stage but are not recommended for chronic use. For individuals who have recurrent symptoms uncontrolled by other methods, a surgical or ablative approach may be used. The objective of the ablative approach is to stabilize the deficit to allow central compensation.

For individuals who have a suspected vestibular disorder not clinically diagnosed as benign paroxysmal positional vertigo who receive ENG/VNG test batteries, caloric testing, or rotational chair testing, the evidence includes technology assessments of a large body of literature. Relevant outcomes are test accuracy, symptoms, functional outcomes, and quality of life. Based on review of controlled studies, caloric testing was given a level A recommendation that this test was predictive of loss of vestibular function. Based on a prospective study assessing a narrow spectrum of individuals with the suspected vestibular dysfunction, or well-designed retrospective study compared with the criterion standard test, rotational chair testing was also given a level A recommendation. These tests are both considered criterion standard tests of vestibular function. ENG/VNG test batteries, which may include caloric testing, are also established methods of assessing loss of vestibular function. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a suspected vestibular disorder not clinically diagnosed as benign paroxysmal positional vertigo who receive a VEMP testing, the evidence includes mainly association studies. Relevant outcomes are test accuracy, symptoms, functional outcomes, and quality of life. There is a large and rapidly growing literature on VEMP tests for the assessment of otolith function, although most studies have assessed how the cervical VEMP and ocular VEMP change with various disease states. Studies on diagnostic accuracy and clinical utility of this technique for evaluating otolith organs and central pathways are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have clinically diagnosed benign paroxysmal positional vertigo (BPPV) with typical presentation who receive laboratory-based vestibular function tests, the evidence includes technology assessments and practice guidelines. Relevant outcomes are test accuracy, symptoms, functional outcomes, and quality of life. BPPV with a typical presentation can be diagnosed clinically based on history, the Dix-Hallpike maneuver, lateral roll test, and canalith repositioning procedures; thus, laboratory-based vestibular function tests do not add diagnostic information in such routine cases. The evidence is sufficient to determine that the technology is unlikely to improve the net health outcome.

CODING

Medicare Advantage Plans and Commercial Products

The following CPT code(s) for vestibular function tests with recording code range are covered;

- 92537** Caloric vestibular test with recording, bilateral; bithermal (ie, one warm and one cool irrigation in each ear for a total of four irrigations)
- 92538** Caloric vestibular test with recording, bilateral; monothermal (ie, one irrigation in each ear for a total of two irrigations)
- 92540** Basic vestibular evaluation, includes spontaneous nystagmus test with eccentric gaze fixation nystagmus, with recording, positional nystagmus test, minimum of 4 positions, with recording, optokinetic nystagmus test, bidirectional foveal and peripheral stimulation, with recording, and oscillating tracking test, with recording
- 92541** Spontaneous nystagmus test, including gaze and fixation nystagmus, with recording
- 92542** Positional nystagmus test, minimum of 4 positions, with recording
- 92544** Optokinetic nystagmus test, bidirectional, foveal or peripheral stimulation, with recording
- 92545** Oscillating tracking test, with recording
- 92546** Sinusoidal vertical axis rotational testing
- 92547** Use of vertical electrodes (List separately in addition to code for primary procedure)

The following CPT code(s) for Vestibular evoked myogenic potential (VEMP) testing is not covered for Medicare Advantage Plans and not medically necessary for Commercial Plans;

- 92517** Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP)
- 92518** Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; ocular (oVEMP)
- 92519** Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP) and ocular (oVEMP)

RELATED POLICIES

None

PUBLISHED

Provider Update, May 2024
Provider Update, May 2023
Provider Update, May 2022
Provider Update, April 2021
Provider Update, May 2020

REFERENCES:

1. Fife TD, Tusa RJ, Furman JM, et al. Assessment: vestibular testing techniques in adults and children: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. Nov 28 2000;55(10):1431-1441. PMID 11094095
2. Schubert MC. Vestibular function tests. In: Herdman SJ, Clendaniel RA, eds. *Vestibular Rehabilitation. Vol Contemporary Perspectives in Rehabilitation*: F.A. Davis; 2014:178-194.
3. Halmagyi GM, Curthoys IS. Otolith function tests. In: Herdman SJ, Clendaniel RA, eds. *Vestibular Rehabilitation. Vol Contemporary Perspectives in Rehabilitation*: F.A. Davis; 2014:195-225.
4. Hall CD, Herdman SJ, Whitney SL, et al. *Vestibular Rehabilitation for Peripheral Vestibular Hypofunction: An Evidence-Based Clinical Practice Guideline: From the American Physical Therapy Association Neurology Section*. *J Neurol Phys Ther*. Apr 2016;40(2):124-155. PMID 26913496
5. Weber KP, Rosengren SM. Clinical utility of ocular vestibular-evoked myogenic potentials (oVEMPs). *Curr Neurol Neurosci Rep*. May 2015;15(5):22. PMID 25773001
6. Ertl M, Boegle R, Kirsch V, et al. On the impact of examiners on latencies and amplitudes in cervical and ocular vestibular-evoked myogenic potentials evaluated over a large sample (N = 1,038). *Eur Arch Otorhinolaryngol*. Feb 2016;273(2):317-323. PMID 25628238
7. Colebatch JG, Rosengren SM, Welgampola MS. Vestibular-evoked myogenic potentials. *Handb Clin Neurol*. 2016;137:133-155. PMID 27638068

8. Papathanasiou ES, Murofushi T, Akin FW, et al. International guidelines for the clinical application of cervical vestibular evoked myogenic potentials: an expert consensus report. Clin Neurophysiol. Apr 2014;125(4):658-666. PMID 24513390
9. Halker RB, Barrs DM, Wellik KE, et al. Establishing a diagnosis of benign paroxysmal positional vertigo through the dix-hallpike and side-lying maneuvers: a critically appraised topic. Neurologist. May 2008;14(3):201-204. PMID 18469678
10. Bhattacharyya N, Baugh RF, Orvidas L, et al. Clinical practice guideline: benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. Nov 2008;139(5 Suppl 4):S47-81. PMID 18973840
11. American Academy of Audiology. Position statement on the audiologist's role in the diagnosis and treatment of vestibular disorders. 2017; <http://www.audiology.org/publications-resources/document-library/position-statement-audiologists-role-diagnosis-treatment>. Accessed December 19, 2022.
12. American Academy of Audiology. Scope of practice. Audiol Today. 2004;15(3):44-45.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

